Birch Pollen Allergy - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 49
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BAC18BF9B94EN
Leaflet:

Download PDF Leaflet

Birch Pollen Allergy - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Birch Pollen Allergy - Pipeline Review, H2 2016’, provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
  • The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Birch Pollen Allergy Overview
Therapeutics Development
Pipeline Products for Birch Pollen Allergy - Overview
Birch Pollen Allergy - Therapeutics under Development by Companies
Birch Pollen Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Birch Pollen Allergy - Products under Development by Companies
Birch Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
HAL Allergy BV
Stallergenes SAS
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AllerT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Birch Pollen Allergoid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STG-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Birch Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Birch Pollen Allergy - Dormant Projects
Birch Pollen Allergy - Discontinued Products
Birch Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Birch Pollen Allergy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
Birch Pollen Allergy - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
Birch Pollen Allergy - Pipeline by Anergis SA, H2 2016
Birch Pollen Allergy - Pipeline by Biomay AG, H2 2016
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016
Birch Pollen Allergy - Pipeline by Stallergenes SAS, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Birch Pollen Allergy - Dormant Projects, H2 2016
Birch Pollen Allergy - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Birch Pollen Allergy, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

ALK-Abello A/S
Allergopharma GmbH & Co. KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
HAL Allergy BV
Stallergenes SAS
Skip to top


Grass Pollen Allergy - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 56 pages

Ask Your Question

Birch Pollen Allergy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: